Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis research hub

A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis

This clinical trial is testing whether two medicines, pemafibrate and tofogliflozin, taken together can treat a severe fatty liver condition called NASH. The 48-week study aims to see if this combination safely lowers liver inflammation and prevents liver scarring from getting worse in adults without advanced liver damage.